Literature DB >> 3079773

Sex difference in human growth hormone (GH) response to intravenous human pancreatic GH-releasing hormone administration in young adults.

A E Smals, G F Pieters, A G Smals, T J Benraad, J Van Laarhoven, P W Kloppenborg.   

Abstract

Intravenous administration of a 100-micrograms dose of human pancreatic GH-releasing hormone (human pancreatic GHRH1-44, indicated by GHRH) disclosed a sex difference in GH responsiveness. The maximum GH increments [41 +/- 11 (SEM) vs. 15 +/- 4 ng/ml, P* less than 0.05] and the areas under the curves (419 +/- 105 vs. 148 +/- 53 area U, P* less than 0.05) were significantly higher in 12 men than in 10 women. No significant correlation was found in either group between the basal plasma estradiol or testosterone levels and the maximum or integrated GH response to GHRH. Serum PRL levels significantly increased in both groups within 5 min after GHRH injection (men, P less than 0.001 vs. t = 0; women, P less than 0.05 vs. t = 0). The areas under the curves of the PRL responses (355 +/- 184 vs. 189 +/- 73 area U) and the maximum PRL increments (58 +/- 18 vs. 36 +/- 6 mU/l, P* greater than 0.10) were similar. In conclusion, a sex difference in GH responsiveness to GHRH was found between young adult men and women. Recent in vivo and in vitro data reveal a similar sex difference in rodents and an enhancing effect of androgens, but not estrogens, on the GH response to GHRH. These findings support the theory that in humans testosterone also plays a key role in the genesis of this sex difference.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3079773     DOI: 10.1210/jcem-62-2-336

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa.

Authors:  M Giusti; L Foppiani; P Ponzani; C M Cuttica; M R Falivene; S Valenti
Journal:  J Endocrinol Invest       Date:  1997-05       Impact factor: 4.256

2.  Morphological and functional study of the GH-immunoreactive adenohypophyseal cells in ovariectomized rats.

Authors:  J Carretero; F Sánchez; M Montero; E Blanco; J M Riesco; E Carbajo; R González; R Vázquez
Journal:  Histochem J       Date:  1990-12

Review 3.  Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system.

Authors:  E Arvat; L Gianotti; R Giordano; F Broglio; M Maccario; F Lanfranco; G Muccioli; M Papotti; A Graziani; E Ghigo; R Deghenghi
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

4.  Does SMS 201-995 normalize growth hormone secretion in acromegaly? GH day profiles and GH concentrations after oral glucose loading.

Authors:  P A van Liessum; G F Pieters; A G Smals; L M Swinkels; T J Benraad; P W Kloppenborg
Journal:  J Endocrinol Invest       Date:  1989-09       Impact factor: 4.256

5.  Arginine induced growth hormone (hGH) response and paradoxical hGH secretion stimulated by TRH in diabetes mellitus.

Authors:  G Winkler; L Gerö; T Halmos; A Grósz; G Gefferth; P Varga; G Tamás
Journal:  Acta Diabetol Lat       Date:  1987 Apr-Jun

6.  Prolactin response to growth hormone-releasing hormone during chronic thyrotropin-releasing hormone infusion in the treatment of amyotrophic lateral sclerosis.

Authors:  P G Chiodini; R Attanasio; A Liuzzi; R Cozzi; P Orlandi; C De Palo; D Dallabonzana; F Girotti; D Testa
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

7.  Sex differences in growth hormone response to growth hormone-releasing hormone.

Authors:  P Benito; L Avila; M S Corpas; J A Jiménez; L Cacicedo; F Sánchez Franco
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

8.  Regulatory mechanisms of growth hormone secretion are sexually dimorphic.

Authors:  C A Jaffe; B Ocampo-Lim; W Guo; K Krueger; I Sugahara; R DeMott-Friberg; M Bermann; A L Barkan
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.